Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 7,513 articles

Articles by Daniel Marsh

Focus Universal Shares Surge 517% on AI Engine Reveal
Analysis

Focus Universal Shares Surge 517% on AI Engine Reveal

Focus Universal (FCUV) shares jumped 517% on Friday after unveiling an AI document-processing engine, but the surge came on trading volume 147 times its disclosed share count, raising sustainability concerns.

FCUV
Nvidia Retakes Crown as Cloud Giants Pour $140B into AI Infrastructure
Markets

Nvidia Retakes Crown as Cloud Giants Pour $140B into AI Infrastructure

Nvidia reclaimed the world's most valuable company title Friday as Amazon, Alphabet, and Microsoft disclosed a combined $140.1 billion in quarterly cloud infrastructure spending, signaling sustained AI demand.

NVDA AAPL AMZN GOOGL MSFT AMD TSM
India VIX Slips 16% as Liquidity Concerns Cloud Market Calm
Markets

India VIX Slips 16% as Liquidity Concerns Cloud Market Calm

India VIX dropped 16.2% to 11.755 as NIFTY 50 gained 2.6%, but derivatives turnover fell 27.1% due to new funding rules, raising questions about the reliability of the volatility signal.

GLD
Guyana's Oil Revenue Share to Rise as Stabroek Cost Recovery Hits $55B
Markets

Guyana's Oil Revenue Share to Rise as Stabroek Cost Recovery Hits $55B

Stabroek consortium recoups $55B in costs ahead of schedule, shifting Guyana to profit-sharing. Exxon's entitlement dips 100k bpd, but free cash flow expected to double by 2030.

XOM CVX USO
2027 Social Security COLA Projected at 3.6%-3.8%, Adding $50B to Outlays
Economy

2027 Social Security COLA Projected at 3.6%-3.8%, Adding $50B to Outlays

Initial estimates put the 2027 Social Security COLA at 3.6%-3.8%, boosting average monthly benefits by $75-$79 and adding ~$50 billion in annual outlays, with modest consumer impact.

SPY QQQ GLD SLV USO UNG
FTSE 100 Gains Concentrated in Two-Day Rally; Energy and Earnings in Focus
Markets

FTSE 100 Gains Concentrated in Two-Day Rally; Energy and Earnings in Focus

The FTSE 100 advanced 1.23% last week, but nearly all gains came from a two-day rally. Key earnings from BP, HSBC, and Glencore are due next week.

UL RR BP HSBC NXT USO
AI Cash Flow Concerns Split Tech Stocks as S&P 500 Gains 1.1%
Markets

AI Cash Flow Concerns Split Tech Stocks as S&P 500 Gains 1.1%

Wall Street ended higher last week, but AI investment scrutiny deepened. Microsoft and Amazon rallied on strong cloud results, while Apple and Meta slid on cash flow worries.

MSFT AMZN AAPL META PLTR AMD LLY
Global Markets Wrap: Barclays Surges, Yamanashi Split, Coldcard Breach
Markets

Global Markets Wrap: Barclays Surges, Yamanashi Split, Coldcard Breach

Barclays shares soar 442% from 2020 lows, Yamanashi Chuo Bank plans a stock split, and Coldcard bitcoin wallets suffer a $70M security breach.

BCS MSFT BRZE
Oracle Stock Surges 13% on Gemini Deal, Cloud Growth
Analysis

Oracle Stock Surges 13% on Gemini Deal, Cloud Growth

Oracle shares climbed 13% this week after announcing a Gemini AI partnership with Alphabet and reporting strong cloud growth. Backlog conversion covers 85% of its FY2027 revenue target.

ORCL GOOGL MSFT AMZN AMD
Inno Holdings Stock Plunges 54% on Share-Count Revision
Markets

Inno Holdings Stock Plunges 54% on Share-Count Revision

Inno Holdings shares plunged 54% after trading resumed, as a revised share count implies a $45M valuation, below its $60M ATM program ceiling.

INHD NDAQ
Replimune Surges 107% as FDA Panel Backs RP1 Despite Data Discrepancies
Analysis

Replimune Surges 107% as FDA Panel Backs RP1 Despite Data Discrepancies

Replimune shares soared 107% after an FDA panel endorsed RP1's efficacy data, despite conflicting response rates. The FDA decision is expected by August 2.

REPL BMY IOVA BMO
Integer Holdings Soars 20% on KKR Takeover Speculation
Markets

Integer Holdings Soars 20% on KKR Takeover Speculation

Integer Holdings jumped 20% on reports that KKR is in advanced talks to acquire the medical device maker for around $127 per share, leaving a narrow spread for investors.

ITGR KKR